PHIO News and Press, Phio Pharmaceuticals Corp. From 05/05/22

Phio Pharmaceuticals Announces Senior Leadership Personnel Change PR Newswire MARLBOROUGH, Mass. , May 5, 2022 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company developing the next generation of therapeutics...

Phio Pharmaceuticals Announces Trial-In-Progress Poster at ASCO 2022 PR Newswire MARLBOROUGH, Mass. , May 3, 2022 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company developing the next generation of therapeut...

Phio Pharmaceuticals Announces Upcoming Presentation of PH-894 Data at ASGCT 25th Annual Meeting 2022 PR Newswire Marlborough, Mass. , May 2, 2022 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company developing the nex...

Phio Pharmaceuticals Announces the Appointment of Patricia A. Bradford to its Board of Directors PR Newswire MARLBOROUGH, Mass. , May 2, 2022 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company developing the ...

Phio Pharmaceuticals (NASDAQ:PHIO) said it opened patient enrollment in a phase 1b trial of PH-762 to treat advanced melanoma, a type of skin cancer. "We are excited to advance our first-in-human clinical trial for our lead program, PH-762, to treat patients with melanoma. The start of this c...

Phio Pharmaceuticals Announces the Start of its Phase 1b Clinical Trial of PH-762 for the Treatment of Advanced Melanoma PR Newswire MARLBOROUGH, Mass. , April 26, 2022 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnol...

Gainers: Clarus Therapeutics Holdings (CRXT) +87%. Winc (WBEV) +27%. AlloVir (ALVR) +26%. NexImmune (NEXI) +24%. Charah Solutions (CHRA) +22%. Target Hospitality (TH) +20%. Phio Pharmaceuticals (PHIO) +20%. Healthcare Services Group (HCSG) +19%. CEL-SCI (CVM) +18%. Biophytis (BPTS) +17%. Lose...

Phio Pharmaceuticals Selected to Present at the Tumor Immune Microenvironment Workshop of the Society for Immunotherapy of Cancer PR Newswire MARLBOROUGH, Mass. , April 18, 2022 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage b...

The following slide deck was published by Phio Pharmaceuticals Corp. in conjunction with this event. For further details see: Phio Pharmaceuticals (PHIO) Presents at the American Association for Cancer Research Annual Meeting 2022 - Slideshow

Gainers: Lexaria Bioscience (LEXX) +23%. Rite Aid (RAD) +14%. Inozyme Pharma (INZY) +12%. Finch Therapeutics (FNCH) +11%. Valneva (VALN) +9%. Losers: Protagonist Therapeutics (PTGX) -23%. Lixte Biotechnology (LIXT) -10%. Biofrontera (BFRI) ...